Dyne Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing muscle disease therapeutics. The company is developing product candidates targeting serious muscle diseases, leveraging its proprietary FORCE platform technology. Dyne has a license agreement with the University of Mons (UMONS) covering intellectual property relevant to its product candidates and technology development efforts.
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001193125-26-084178 | EDGAR | 117K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028356 | EDGAR | 108K words |
| 2024-03-05 | 2023-12-31 | 0000950170-24-025402 | EDGAR | 99K words |
| 2023-03-02 | 2022-12-31 | 0000950170-23-005708 | EDGAR | 97K words |
| 2022-03-10 | 2021-12-31 | 0000950170-22-003290 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010726 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-29 | 2026-06-30 | 0001193125-26-323639 | EDGAR | 75K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-266882 | EDGAR | 76K words |
| 2025-07-28 | 2025-06-30 | 0000950170-25-099161 | EDGAR | 74K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066386 | EDGAR | 67K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124572 | EDGAR | 66K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095527 | EDGAR | 65K words |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052066 | EDGAR | 64K words |
| 2023-10-30 | 2023-09-30 | 0000950170-23-056121 | EDGAR | 63K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037585 | EDGAR | 63K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020839 | EDGAR | 60K words |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021546 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014474 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-29 | 0001193125-26-323940 | EDGAR | 2K words |
| 2026-07-22 | 0001193125-26-312571 | EDGAR | 1K words |
| 2026-07-20 | 0001193125-26-308343 | EDGAR | 1K words |
| 2026-03-02 | 0001193125-26-084207 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-009782 | EDGAR | 4K words |
| 2025-12-23 | 0001193125-25-329511 | EDGAR | 1K words |
| 2025-12-10 | 0001193125-25-314249 | EDGAR | 1K words |
| 2025-12-08 | 0001193125-25-311221 | EDGAR | 1K words |
| 2025-12-08 | 0001193125-25-310516 | EDGAR | 5K words |
| 2025-11-05 | 0001193125-25-266979 | EDGAR | 2K words |
100 total filings indexed. 72 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001818794 |
| Ticker | DYN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.dyne-tx.com |
| Listed | 2020-09-17 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/DYN (~200 tokens, structured JSON with cryptographic provenance)